MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.
Washington University, St Louis, Missouri, United States
Dana-Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Baylor University, Houston, Texas, United States
Aurora Cancer Care, Milwaukee, Wisconsin, United States
Phase 1
Recruiting
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorPlatinum-resistant Ovarian CancerPost Anti-PD-1 Melanoma2L+ Cervical CancerNeoadjuvant MelanomaNeoadjuvant Non-Small Cell Lung CancerPost Anti-PD-(L)1 Non-Small Cell Lung CancerPost Anti-PD-(L)1 Small Cell Lung CancerThird Line or Later (3L+) HER2+ Breast CancerSecond or Third Line (2L/3L) Cervical CancerThird-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United StatesEst. completion Aug 2027